Cerebral palsy (CP) is a common cause of movement disorders in children. The upper motor neuron syndrome of CP leads to several types of muscle overactivity, including spasticity. Reduction of muscle overactivity may be an important treatment goal, to improve comfort, care, and active function and to prevent future musculoskeletal complications. After a comprehensive team evaluation, a treatment plan is generated. Treatments may include physical and occupational therapy, oral medications, botulinum toxin and/or phenol injections, intrathecal baclofen, selective dorsal rhizotomy, and orthopedic surgery. Successful and early prevention of contracture may reduce the need for later corrective surgery.
INTRODUCTION
Cerebral palsy (CP) is the most common movement disorder in children, occurring in 2-3 of every 1000 live births. 1 It is significantly more common in lower-birthweight infants, and half of all cases occur in infants with a birthweight of less than a kilogram. 2 The definition of CP has recently been updated by The Executive Committee for the Definition of Cerebral Palsy. 3 Previous definitions focused exclusively on CP as a motor disorder, as in the 1978 definition by Nelson and Ellenberg, 4 in which CP is "characterized by aberrant control of movement or posture of a patient, appearing early in life (secondary to a CNS lesion, damage or dysfunction), and not the result of a recognized progressive or degenerative brain disease." The recent update retains the emphasis on the motor disorder, but adds the likelihood that the patient will also have other impairments, which may be equally or more significant: "Cerebral palsy (CP) describes a group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, cognition, communication, perception, and/or behavior, and/or by a seizure disorder." 3 Thus CP is a group of movement disorders that have in common that they are caused by static injury to the developing brain. The definitive diagnosis can only be made after a period of observation in which no progression of symptoms is observed, and any worsening of motor function over time indicates a different diagnosis must be sought. The child with CP may also have significant nonmotor impairments, including communication, intellectual function, learning disabilities, epilepsy, and sensory impairment. This article focuses on the treatment of the movement disorder aspects of CP.
Despite the high prevalence of CP compared with many other neurologic disorders, relatively little research has been done on its prevention and treatment. This is perhaps partly from funding priorities being driven by the more vocal proponents for other disorders, but also because CP encompasses a heterogeneous group of etiologies and wide variation in clinical presentation. Even standardized terminology for the clinical aspects of the disorder has been lacking, making comparisons of populations and outcome measures problematic. Some progress in this areas has recently been made by the Task Force on Childhood Motor Disorders. 5 This NIH-supported effort developed detailed operational definitions of spasticity, dystonia, and rigidity, which are applicable to clinical features of hypertonic movement disorders in children and which may aid in developing better inclusion criteria and outcome evaluations in future trials. A further problem in CP research is the difficulty of conducting blinded, placebo-controlled trials in this disorder. Such trials are the norm for oral medications, in which it is easy to mask the identity of the active drug and the placebo. Structuring such trials is far more problematic for other types of interventions, including physical therapy (PT) and surgery, yet these are currently (along with botulinum toxin injections) the most common and beneficial interventions in CP. Randomization without blinding is the alternative, and this methodology is commonly used in this population. In addition to the problems of structure, trials of surgical or PT interventions may be arduous, far more so than a comparable test of an oral medication. Performing such trials is difficult, and the clinicians and families who participate deserve a great deal of credit.
As an upper motor neuron disorder, CP gives rise to both positive and negative symptoms. 6 The positive symptoms include muscle overactivity and increased deep tendon reflexes, while the negative ones are weakness and loss of fine motor dexterity. In general, only the positive symptoms are amenable to pharmacologic therapy. Unfortunately, in many cases the negative symptoms have the greater effect on patient function.
EVALUATION AND TREATMENT
Along with a revised definition of CP, The Executive Committee for the Definition of Cerebral Palsy also recently proposed an updates classification scheme, 3 which includes motor abnormalities, associated impairments, anatomic and radiologic findings, and causation and timing. In this scheme, the movement disorder is classified as spastic, dystonic, athetotic, ataxic, or mixed. 7 Classification by anatomic distribution is based on affected body regions or specific type of movement and may include bulbar or trunk involvement as well as the canonical descriptions of limb involvement (Table 1) . 7 Motor abnormalities are also described in terms of their functional impact, ideally using one or more objective functional scales. Associated impairments are classified as present or absent, and, if present, their functional impact is assessed with standard tools.
Spasticity is defined as an increase in velocity-dependent tonic stretch reflexes with exaggerated tendon jerks. 8 "Spasticity" is often used to encompass all forms of muscle overactivity, although Mayer and Herman 9 have pointed out that spasticity is only one type of muscle overactivity in the upper motor neuron syndrome. Others include clonus, flexor spasms, cocontraction, and dystonia. "Dystonia" is defined as a movement disorder in which involuntary, sustained, or intermittent muscle contractions cause twisting and repetitive movements, abnormal postures, or both. 5 Cocontraction of agonists and antagonists sets the stage for rigidity, characterized by resistance at very low velocities of movement, absence of return of the limb to a fixed posture or angle, and lack of synergistic movement about the joint caused by movement in distant muscle groups. 5 The distinctions between these various forms of overactivity may be more than academic, as some forms may respond more to certain medications than to others. To date, little research has been done with these distinctions in mind, making it difficult to test this hypothesis.
Spasticity per se can be roughly quantified in the clinic with the Modified Ashworth scale, a six-point measure of limb resistance to passive movement (see Table 2 ). The Modified Ashworth scale has been widely used as an endpoint in clinical trials; has the advantage of being simple to administer; and, with training, can be a reproducible measure for determining the efficacy of an intervention. It is, however, important for the clinician to distinguish resistance because of spasticity from resistance because of fibrotic changes in the muscle, which will not be amenable to pharmacologic interventions. The goal of treating muscle overactivity in CP is to improve some aspect of care, comfort, or active function and to prevent future musculoskeletal complications such as contracture and hip subluxation. Thus, treatment must begin with a comprehensive evaluation by a team that includes a pediatric neurologist, physical therapist, occupational therapist, social worker, education specialist, and other professionals, who together develop a complete picture of the child in the home and school environment. Working with the family, the team develops a treatment plan that considers current abilities and disabilities, child and family goals, limitations such as finances and transportation, and other factors. Within the overall treatment plan, reduction of muscle overactivity will likely become an important strategy but should never be an end in itself.
Physical therapy and regular physical activity form the basis of every treatment program. Oral medications may have a role in global tone reduction, although the concern for cognitive side effects is likely to limit their use. Injections of botulinum toxin or phenol provide focal tone reduction. Intrathecal baclofen may be appropriate for patients with significant and widespread muscle overactivity, especially in the lower extremities. Selective dorsal rhizotomy may be an option for patients with good underlying strength. Early treatment with any of these therapies may reduce the need for later orthopedic surgery.
PHYSICAL THERAPY
The goal of the PT program is to develop strength, maintain range of motion, and improve coordination while engaging the child in activities he or she naturally enjoys. Maintaining the full range of motion in tight muscles is of paramount importance, to prevent development of contracture. This can often be accomplished by a reasonably active child through normal activities of play, but compensatory strategies and postures may prevent the full range of motion of some affected muscle groups. Thus, regular stretching continues to be required. This usually requires a parent to implement a stretching program, under the guidance of the physical therapist. Ensuring compliance with this program may be one of the major challenges of treatment in CP. If successful, it allows the therapist to devote more office time to other PT activities, which can lead to better progress in developing more complex motor skills. Stretching at least 1 min every 12 h is recommended. 11 Other forms of PT may include hydrotherapy and horseback riding 12 and modalities such as biofeedback, heat, cold, and electrical stimulation. 13 Constraint-induced therapy (CIT) is an old technique undergoing significant renewed interest for children with hemiplegia. This resurgence is based partly on the growing understanding of the brain's plasticity and stems from good results in adult stroke patients. 14 The basic technique is to prevent the patient from using the "good" upper limb to perform functional tasks by constraining its movement. This forces the impaired limb to take over, greatly increasing its use and presumably "rewiring" the brain to work around the damaged motor control region. A recent trial by Taub et al. 15 indicates its potential in CP, but also the challenges of incorporation into the therapeutic program. Eighteen children with hemiparesis (ages 7 months to 8 years) were randomly assigned to CIT or conventional PT. Constraint was applied for 6 h per day for 21 consecutive days. After treatment, children undergoing CIT acquired significantly more new classes of motor skills (9 versus 2) and had more and better-quality movements of the affected arm. Tested in the lab, these children used their affected arm in more than 50% of spontaneous motor tasks versus only 2% for those not receiving CIT. Benefits were sustained at 6 months. Despite these promising results, physical therapists and parents alike are well aware of the difficulty of imposing this type of rigorous program on a child, and it is not yet clear whether a less burdensome treatment program may be able to offer similar benefits. More research is clearly in order.
It is widely recognized that children with CP are often weak. Surprisingly, however, the need for strength training is much less appreciated, despite that increased strength can improve ambulation. 16, 17 Strength training can also provide psychological benefits in adolescents, leading to increased feeling of well-being and participation in school activities. 18 Dynamic equinus is commonly treated with an anklefoot orthosis (AFO). Carlson et al. 19 showed that AFOs can significantly increase ankle dorsiflexion at foot strike, a key measure of equinus, although no improvements in gait were seen. When equinus inhibits standing in the preambulatory child, an AFO may promote the sit-to-stand transition. 20 Balance problems may be amenable to use of walking aids. A walker may aid the child with spastic diplegia, for whom posterior balance is a principal problem. If forward balance is also impaired, crutches may be required.
Serial casting to prevent fixed contracture has a long history in the treatment of CP but is not without controversy. In recent years it has often been replaced with or become an adjunct to botulinum toxin type A (BTX-A) injections. Several randomized controlled trials have compared the efficacy of casting alone, BTX-A alone, or both treatments together. Corry et al. 21 showed that the two treatments were equally efficacious in reducing tone and improving ankle kinematics, although the BTX-A group had fewer side effects and maintained benefit slightly longer. Similarly, Flett et al. 22 found BTX-A to be as effective as casting in reducing calf tightness, and it was preferred by parents for its convenience. Bottos et al. 23 compared BTX-A alone to BTX-A plus casting and found that either treatment led to reduced tone, but that the combination produced longer-lasting effects on tone, standing, and gait. Kay et al. 24 used the opposite design, comparing casting alone to the combination treatment for reduction of ankle equinus, and found no difference in the duration of casting required for treatment. Surprisingly, results were better and longer lasting for the casting-alone group. Finally, Ackman et al. 25 compared BTX-A alone, casting alone (with BTX-A placebo), and combination treatment for dynamic equinus. BTX-A alone performed worst, providing no significant benefit at any time in ankle kinematics, stride length, or velocity, while both casting groups did improve.
ORAL MEDICATIONS
The principal oral medications used in the treatment of CP are benzodiazepines, baclofen, tizanidine, and dantrolene sodium. All tend to produce sedation and drowsiness, which often limits their use in children. Relatively few double-blind trials of these agents have been performed in the CP population, and many of the trials supporting the efficacy of these agents date back more than 20 years.
Benzodiazepines
The benzodiazepines facilitate transmission at GABA-A receptors, one of the principal types of inhibitory synapses in the CNS. This results in increased inhibition and reduces mono-and polysynaptic transmission. 26 Diazepam is the most commonly used agent. Mathew et al. 27 showed in a trial of 180 children that a bedtime dose of diazepam was more effective than placebo in improving daytime spasticity and range of passive movement without causing drowsiness. Early trials from the 1960s indicate diazepam's effectiveness in reducing spasticity, especially in younger children and those with athetosis. 28, 29 One trial of clonazepam has also shown antispasticity efficacy in the CP population.
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Baclofen
Baclofen is a GABA-B agonist. A single trial of oral baclofen in CP demonstrated superiority to placebo in reducing spasticity and improving passive and active limb movements. 31 Despite the relative paucity of clinical support for its use, oral baclofen is frequently prescribed for children with CP.
Tizanidine
Tizanidine is an ␣-2 adrenergic agonist, which prevents the release of excitatory amino acids from spinal interneurons. 26 A single Russian study of tizanidine indicates its utility for treatment of CP, although the results are available in English only in abstract form, making it difficult to judge the full study design. 32 
Dantrolene sodium
This agent acts at the muscle, reducing calcium efflux and thereby decoupling excitation and contraction. Joynt and Leonard 33 found no clinical benefit from treatment in 20 CP children, despite physiologic evidence of muscle force reduction. In contrast, Nogen 34 found that dantrolene was effective at reducing spasticity and was more effective than diazepam in some patients. Nogen also showed that a combination of the two could be even more effective than either alone. Chyatte et al. 35 also showed that dantrolene improved spasticity, although with little improvement in activities of daily living.
BOTULINUM TOXIN AND PHENOL INJECTIONS
The introduction of botulinum toxin for the relief of focal muscle overactivity was a major advance in the treatment of CP. It was not the first agent used for chemodenervation; however, injections of phenol or ethyl alcohol were used to treat spasticity for several decades before the advent of BTX. The advantage of BTX is its highly predictable muscle-weakening effect versus the somewhat less predictable effects of the other two agents, the comparative ease of administration, and the potential for fewer and less permanent side effects.
Botulinum toxin
Pharmacology. There are seven serotypes of botulinum toxin, A through G, all produced by the bacterium Clostridium botulinum. 36 Each is a protease that cleaves one or more vesicle fusion proteins at the neuromuscular junction, thereby preventing release of acetylcholine and inducing muscle weakness. Each toxin differs in its exact target, duration of action, and toxicity. The measure of potency of BTX is the "mouse unit," defined as the quantity of toxin that causes death in 50% of mice of a defined weight and strain. 36 Because of manufacturing and intrinsic molecular differences, units of the various commercial toxins are not equivalent.
Rough conversions indicate that one Botox unit is approximately equal in potency to 4 Dysport units and 50 MyoBloc units. Because of differences in side effect profiles, no standard conversion among products has been widely accepted among expert injectors. Botox and Dysport are supplied as freeze-dried powders, which are reconstituted in sterile saline before use. MyoBloc is supplied as a solution, which may be diluted or used as supplied.
Clinical practice. The most appropriate candidate for BTX injection is a patient for whom the weakening of a limited number of muscles has the potential to provide meaningful benefit in care, comfort, or active function. BTX may be used with other treatments, such as oral medications or intrathecal baclofen, to provide focal tone reduction. BTX is injected directly into overactive muscle. Electromyography, electrical stimulation, or sonography may be used to guide injections in difficult-toreach muscles, while palpation is usually sufficient for superficial or prominent muscles. Clinical benefit is usually seen within several days, and the peak benefit occurs at approximately 4 weeks. 36 Benefit gradually declines, typically requiring reinjection at 3-4 months. Injections more frequently than 3 months increase the risk for development of neutralizing antibodies, a major concern when BTX is used at the high doses needed to treat spasticity. Antibody development precludes further use of the same serotype toxin, but it is possible to switch serotypes, from A to B or B to A.
Dosing guidelines for use of Botox in pediatric spasticity have been proposed to aid injectors. 37 Sponsored by WE MOVE, a not-for-profit movement disorders educational organization, these guidelines were developed by an international panel of experts in the treatment of pediatric spasticity and reflect their long experience in the use of this therapy in this population. The guidelines suggest starting and maintenance doses for each of the muscles most likely to be involved in the common clinical patterns in the upper motor neuron syndrome. The guidelines also recommend a total ceiling dose per injection visit of either 16 Units Botox per kilogram, or 400 Units, whichever is less, again to minimize antibody formation.
Clinical trials. BTX-A has been tested in more than 40 clinical trials in CP. Its ability to reduce spasticity in both the upper and lower limbs has been proven repeatedly. 21-24,38 -44 What is less definitely proven is its effect on function. 37 Many clinicians believe the difficulty of demonstrating a functional benefit has more to do with the structure of trials and the deficiencies of measuring tools than with the drug itself. Measures that combine effects for the entire body may be inappropriate for detection of functional improvement in one small region, such as the hand, despite that the improvement provides a significant benefit to the child. The development of more targeted measures is currently underway, and preliminary results confirm the functional benefits clinicians have reported. 23, 39, 40, 42 For example, in a single-blind trial, Steenbeek et al. 39 showed that BTX-A administered to the lower limbs allowed 9 of 11 subjects to significantly improve on 18 of 33 individually set goals for therapy. Fehlings et al. 40 showed that BTX-A administered to the upper limb plus PT led to more significant improvement in self-care than PT alone.
Phenol and ethyl alcohol
The use of these two agents for focal spasticity reduction predates the introduction of BTX. They have largely been replaced by BTX, but they still can be useful, especially for very powerful muscles inadequately treated by recommended doses of BTX, or when cost is a concern or antibody resistance to BTX has developed. Both agents are injected directly adjacent to a motor nerve, either where it enters the muscle (motor nerve block) or at the branching of the nerve within the muscle (motor point block). 45 Both types of injections require considerable skill on the part of the clinician and carry the risk of significant adverse effects, including muscle necrosis, vascular complications, and dysesthesias. Pain is more likely after treatment of a mixed nerve.
Most recent studies of these agents have been in adults, and therefore little modern literature is available to analyze their potential in children. Two recent studies have compared phenol treatment to botulinum toxin in CP. Wong et al. 46 compared BTX-A to phenol in 27 ambulatory children with lower limb spasticity and gait dysfunction. Sixteen received BTX-A, and 11 received phenol motor point blocks. Gait analysis at 1 week before and 2 months after treatment showed superior results for BTX-A, with fewer adverse effects. In a retrospective study of 68 patients, most of whom had CP, Gooch and Patton 47 showed that adverse effects from either treatment were infrequent and that using them in combination allowed many more muscles to be injected.
INTRATHECAL BACLOFEN
Delivery of baclofen to the intrathecal space (ITB) dramatically lowers the amount of baclofen administered. This dose reduction is possible because the drug is delivered in the direct proximity of overactive spinal synaptic connections, rather than systemically, thus significantly reducing the cognitive side effects that limit the utility of oral antispasmodics. 48 Baclofen is delivered to the intrathecal space with the Synchromed infusion system (Medtronic, Minneapolis, MN, USA), consisting of a pump and drug reservoir implanted subcutaneously in the abdomen and a catheter inserted most commonly at the T11-T12 level. The pump is remotely programmable via an on-board computer and telemetry wand, linked to a laptop computer. The reservoir, which contains an alarm indicating low drug level, is refilled percutaneously, usually every 9 -12 weeks but up to 24 weeks under normal conditions. The appropriate candidate for ITB has lower extremity spasticity of 3 or greater on the Ashworth scale, indicating significant muscle overactivity. A bolus infusion is used as a screening tool, with a decrease in one unit on the Ashworth scale being the standard for proceeding in most centers.
Controlled clinical trials of ITB indicate its ability to reduce muscle overactivity and improve function over prolonged treatment periods. 48 -51 Potential benefits include reduced spasticity, easier care and transfers, and reduced pain. The effects on ambulation may be unpredictable, with some patients improving, others remaining unchanged, and others worsening. 52 ITB may reduce the need for orthopedic surgeries to the lower limbs, according to a study by Gerszten et al. 53 They studied 48 patients receiving pumps, of whom 28 had been recommended for but had not yet received orthopedic intervention. In 18 of 28, surgery was not deemed necessary after the pump implantation because of reduction in lower extremity muscle overactivity.
ITB therapy does carry the risk for significant complications. Infection, pump malfunction, and catheter kinking or withdrawal are all important concerns. 54 Lifethreatening drug withdrawal is a possibility, and families must be educated about this concern and how to recognize its symptoms. 55 Baclofen overdose, because of programming error, is also a possibility.
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SELECTIVE DORSAL RHIZOTOMY
Selective dorsal rhizotomy (SDR) cuts overactive dorsal nerve rootlets, reducing aberrant afferent activity from muscle spindles and reducing spasticity. A lumbar laminectomy or laminoplasty is performed. Individual nerve rootlets from L4 or L5 to S1 are stimulated. Those giving rise to excessive muscle activity are severed. Typically 25 to 60% of nerve rootlets are cut.
Multiple controlled trials have demonstrated the ability of SDR to reduce lower limb spasticity and increase range of motion. 57 Improvements have been seen in gross motor function, self-care, and gait. 58, 59 SDR plus PT has been shown in two trials 60, 61 to be superior to PT alone for improvement of gross motor function and range of motion, although a third trial 62 found no extra benefit from SDR plus PT versus PT alone. The best candidates for surgery are children ages 3-7 years, with spastic diplegia, good trunk control, good leg strength, and isolated leg movements (i.e., leg movements without involuntary involvement of other limbs). 63 Intensive postoperative PT is essential to mobilize the patient and to regain preoperative motor function.
Concern has been raised about an increased risk for scoliosis after SDR, because of the weakening effect of the procedure. Johnson et al. 64 found a higher rate of spinal deformity in patients undergoing SDR than in historical controls, a finding echoed by Steinbok et al. 65 Some evidence indicates SDR can delay or avoid the need for orthopedic surgery later.
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ORTHOPEDIC SURGERY
Despite best management, many children with CP will eventually require orthopedic surgery to correct fixed contracture. The most common sites of surgery are the heel cords for equinus or equinovarus, and the most common operation is tendon lengthening with or without transfer. Some optimism about the state of CP therapy comes from a longitudinal survey by Hagglund et al. 67 They found that the rate of orthopedic surgery for contracture or skeletal deformity decreased from 40% for children born in 1990 -1991 to 15% for children born in 1994 -1995, which they attribute to the advent of other therapies, specifically botulinum toxin, intrathecal baclofen, and rhizotomy. This study emphasizes the potential of early and comprehensive treatment of muscle overactivity to prevent later complications.
